Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Market Update

Julia Lee
December 18, 2018

Market Update

Julia Lee
December 13, 2018

Market Update

Julia Lee
December 5, 2018

Market Update

Julia Lee
December 3, 2018

Market Update

Julia Lee
November 30, 2018

Market Update 28 Nov

Julia Lee
November 29, 2018

November Market Overview

Julia Lee
November 29, 2018

The Spectrum Strategic Income Fund

Bell Direct
November 6, 2018

The Schroder Fixed Income Fund

Bell Direct
November 6, 2018

The Schroder Absolute Return Income Fund

Bell Direct
November 6, 2018

Market Update

Julia Lee
September 21, 2018